Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2006 by Steno Diabetes Center.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Steno Diabetes Center
Information provided by:
Steno Diabetes Center
ClinicalTrials.gov Identifier:
NCT00320008
First received: April 27, 2006
Last updated: October 12, 2006
Last verified: April 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether intensified multifactorial intervention comprising both behaviour modification and polypharmacy can reduce the risk for late diabetic complications compared to standard treatment in patients with type 2 diabetes and microalbuminuria
| Condition | Intervention |
|---|---|
|
Type 2 Diabetes |
Behavioral: Diet Behavioral: Exercise Behavioral: Stop smoking Drug: Glucose lowering therapy Drug: Blood pressure lowering therapy Drug: Lipid lowering therapy |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Steno Diabetes Center:
Primary Outcome Measures:
- Combined cardiovascular endpoint
Secondary Outcome Measures:
- All cause mortality
- Cardiovascular disease mortality
- Stroke
- Myocardial infarction
- Coronary interventions
- Amputations
- Vascular surgery
- Diabetic retinopathy
- Diabetic nephropathy
- Diabetic neuropathy
| Estimated Enrollment: | 160 |
| Study Start Date: | January 1992 |
| Estimated Study Completion Date: | March 2007 |
Eligibility| Ages Eligible for Study: | 40 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Type 2 diabetes
- Microalbuminuria
Exclusion Criteria:
- Stimulated serum C-peptide concentration less than 600 pmol/L
- Pancreatic insufficiency or diabetes secondary to pancreatitis
- Alcohol abuse
- Non-diabetic kidney disease
- Life-threatening disease with death probable within 4 years of study start
Contacts and Locations
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00320008 History of Changes |
| Other Study ID Numbers: | KA92071gm-KA99035g-KA99035gs |
| Study First Received: | April 27, 2006 |
| Last Updated: | October 12, 2006 |
| Health Authority: | Denmark: Ethics Committee |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 22, 2013